Organigram to acquire Aurora Cannabis for C$561 million
Organigram (OGI) will acquire Aurora Cannabis (ACB) for C$561 million, offering C$7.80 per share in cash, stock, or a mix. The deal values Aurora at a 93% premium over its August 10 closing price and a 21% premium over Curaleaf's rejected bid. Aurora shareholders will hold 35% economic ownership and 42% voting rights in the combined entity.
How this was made
The 30-second read
Why it matters
The transaction creates a combined entity with 35% Aurora ownership, synergies of over C$50 million, and a new credit facility, reshaping competitive dynamics.
Market read
The deal is a material M&A event in the cannabis industry, likely moving both stocks and influencing sector sentiment.
What to watch
Regulatory approvals, potential antitrust scrutiny, and the impact of British American Tobacco's involvement on market perception.
Background
Organigram and Aurora are both listed on NASDAQ and TSX, operating in the rapidly evolving cannabis market.
Ticker impact
Organigram announced it will acquire Aurora Cannabis in a C$561 million deal, issuing new shares and cash to fund the purchase.
likely modest downside as investors weigh share issuance and integration costs
The deal involves a sizable cash and share component, increasing Organigram's share count and debt, which typically pressures the acquirer's stock.
Aurora Cannabis shareholders are offered a 93% premium, making the acquisition the primary catalyst for Aurora's stock.
likely strong upside as the market values the premium and potential synergies
A near‑double premium and guaranteed cash component create immediate value for Aurora shareholders.
Market effects
Consolidation in the Canadian cannabis sector may spur further M&A activity and affect peer valuations.
The deal highlights increased foreign investment in Canadian cannabis, potentially boosting sector sentiment in North America.
Large‑cap investors may adjust exposure to cannabis ETFs and related funds worldwide.
Counterpoint
The acquisition could overpay for Aurora, leading to integration challenges and long‑term earnings drag for Organigram.
Key entities
- InvestorBritish American Tobacco
Provides financing through a private placement of Organigram shares.
- LenderATB Financial
Extends a senior secured credit facility of up to $210 million to Organigram.
